Omalizumab, currently used to treat asthma, has been shown to substantially reduce the risk of potentially life-threatening reactions in people aged one and older with multiple common food ...

The agreement is for Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the ...

The cohort included 325 white children (56.4%), with 113 on placebo and 212 on omalizumab; 99 Black children (17.2%), with 30 on placebo and 69 on omalizumab; and 152 children who were Asian ...

News about omalizumab’s use in food allergy is spreading, Wood said. “At least half of families come in with knowledge of the drug and wanting to know more about it,” he said.

During the first period, study participants (N=619) were randomly assigned to receive omalizumab-igec 300mg, Xolair 300mg, omalizumab-igec 150mg, or Xolair 150mg for 12 weeks.

But omalizumab knocks out a skin test response. I could have somebody who has a huge pricked skin test to dust mite and three months later, gone, which is pretty impressive.

Important early studies had shown that omalizumab held promise for our food allergy patients," the study's senior author, Dr. R. Sharon Chinthrajah, told UPI via email.

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions.

Xolair (Omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults with Chronic Rhinosinusitis with Nasal Polyps in Two Phase III Studies ...

A pilot study suggests omalizumab may improve speed, effectiveness, and safety of oral desensitization in children with multiple food allergies; more research is needed to see if effect lasts.

A new guideline from the EAACI provides an evidence-based overview of the use of omalizumab in the management of antihistamine-resistant chronic spontaneous urticaria in adolescents.

Previous studies of omalizumab have indicated that some patients have a return of symptoms within 4 weeks (i.e., before the administration of the next dose). 32,33 Future studies will be needed to ...